Synthon (rights of glatiramer acetate) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Synthon (rights of glatiramer acetate) General Information

Description

The commercialization rights of glatiramer acetate in the United States. It is a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Pharmaceuticals
Acquirer
Primary Office
  • P.O. Box 110487
  • Research Triangle Park
  • Durham, NC 27709
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Synthon (rights of glatiramer acetate) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synthon (rights of glatiramer acetate)‘s full profile, request access.

Request a free trial